VITAMIN D TREATMENT OF PROSTATE CANCER

流行病学数据表明，维生素D可能在 前列腺癌的发病机制。此外，体外和动物研究 研究表明，维生素D可以抑制前列腺癌细胞的生长。 这项研究的目的是检查潜在的临床应用。 维生素D在治疗早期前列腺癌中的作用。男人都是 参加这项研究的人，如果在对他们的前列腺进行初步治疗后 癌症(前列腺癌手术或放射治疗)，他们证明 前列腺癌标志物--前列腺特异性血清水平升高 抗原(PSA)。他们一定是得了A期或B期疾病，而不是 有转移的证据，因此复发率最低。 这项研究的主要终点是显示出 PSA水平升高作为前列腺癌生长放缓的指标，而 关于维生素D治疗(骨化三醇、罗氏)。其他八个 到目前为止，健康的男性都参与了这项研究。其中一个主题是 在开始治疗之前被排除在外，原因是确定了 潜在的代谢性疾病。已经启动了七个主题 骨化三醇疗法。一名受试者因 肾结石的发展。三个受试者已经显示出有益的 对治疗的反应，与PSA的上升速度相比 到治疗开始前的上升速度。 这项研究正在进行中，招募患者的工作仍在继续。

Epidemiologic data suggest that vitamin D may play a role in the pathogenesis of prostate cancer. Moreover, in vitro and animal studies have shown that vitamin D inhibits the growth of prostate cancer cells. This study is designed to examine the potential clinical utility of vitamin D in treating men with early stages of prostate cancer. Men are enrolled into this study if, after primary treatment of their prostate cancer (surgical prostatectomy or radiation therapy), they demonstrate a rising serum level of the prostate tumor marker, Prostatic Specific Antigen (PSA). They must have had stage A or B disease and not have evidence of metastatis, and therefore have minimal recurrent disease. The primary endpoint of the study is to show a slowing of the rate of rise of PSA levels as an index of slowed prostate cancer growth while on Vitamin D therapy (calcitriol, Rocaltrol- Roche). Eight otherwise healthy men have thus far been enrolled in this study. One subject was excluded prior to the initiation of therapy due to the identification of potential metasatic disease. Seven subjects have been initiated on calcitriol therapy. One subject was withdrawn from therapy due to the development of a kidney stone. Three subjects have shown a beneficial response to the therapy, with a slowing of the PSA rate of rise compared to the rate of rise before therapy was initiated. The study is ongoing, and recruitment of patients is continuing.